Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin ’s lymphoma
ConclusionAdding rituximab to LMB chemotherapy in children and adolescents with high-risk mature B-cell non-Hodgkin's lymphoma is highly cost-effective in France.Trial registrationClinicalTrials.gov identifier: NCT01516580.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
More News: Chemotherapy | Children | Economics | France Health | Health Management | Insurance | Lymphoma | Non-Hodgkin's Lymphoma | Rituxan